⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
XtalPi Holdings Announces 2026 Interim Results
prnewswire.com
INCY
LULU
JKS
BNTX
MRNA
PFE
SNY
LLY
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
INCY
Global Regenerative Medicine Market is Projected to Cross the USD 160 Billion Mark by 2034 | DelveInsight
globenewswire.com
NVS
BBIO
PTC
BMRN
SAVA
PFE
CAT
TMO
LH
VERI
INCY
GILD
MRK
REGN
JAZZ
CELU
OMER
Global Regenerative Medicine Market is Projected to Cross the USD 160 Billion Mark by 2034 | DelveInsight
globenewswire.com
NVS
BBIO
CSL
BMRN
PFE
LNZA
TMO
MRK
CYN
INCY
GSK
JAZZ
GILD
CELU
OMER
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
prnewswire.com
INCY
La crème Opzelura® (ruxolitinib) devient le premier inhibiteur de JAK topique sans stéroïdes autorisé dans l'Union européenne pour le traitement des adultes atteints de dermatite atopique modérée
businesswire.com
INCY
La crème Opzelura ® (ruxolitinib) devient le premier inhibiteur de JAK topique sans stéroïdes autorisé dans l'Union européenne pour le traitement des adultes atteints de dermatite atopique modérée
businesswire.com
INCY
Riassunto: Opzelura® (ruxolitinib) crema diventa il primo inibitore mirato di JAK privo di steroidi approvato nell'Unione europea per adulti con dermatite atopica moderata
businesswire.com
INCY
Opzelura ® (ruxolitinib) crema diventa il primo inibitore mirato di JAK privo di steroidi approvato nell'Unione europea per adulti con dermatite atopica moderata
businesswire.com
INCY